Type stringclasses 2
values | Section_id stringclasses 4
values | Primary_id stringlengths 11 11 | Secondary_id stringlengths 0 11 | Statement stringlengths 34 385 | Label stringclasses 2
values | Primary_evidence_index listlengths 1 65 | Secondary_evidence_index listlengths 0 73 | Primary_ct stringlengths 1.11k 16.3k | Secondary_ct stringlengths 101 16.3k | __index_level_0__ stringlengths 36 36 |
|---|---|---|---|---|---|---|---|---|---|---|
Single | Adverse Events | NCT00544167 | Every adverse event in the primary trial occurred once. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00544167', 'Intervention': ['INTERVENTION 1: ', ' Doxorubicin/Cyclophosphamide Then Paclitaxel/Sorafenib', '[Not Specified]'], 'Eligibility': ['Inclusion Criteria:', ' Patients must have histologically-confirmed breast cancer with an interval between definitive surgery that includes axillary... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | ee2287bd-af76-4232-9575-d371fe3257dc | |
Comparison | Eligibility | NCT00675259 | NCT01875367 | Patients with an ImmunoHistoChemistry test result of 3+ are excluded from the primary trial and the secondary trial. | Contradiction | [
15,
18
] | [
0,
15
] | {'Clinical Trial ID': 'NCT00675259', 'Intervention': ['INTERVENTION 1: ', ' Neoadjuvant, Surgery, Adjuvant', " Neoadjuvant chemotherapy : Nab-paclitaxel and carboplatin on days 1, 8, and 15 in combination with bevacizumab on days 1 and 15 administered every 28 days for 5 cycles followed by 1 cycle with Nab-paclitaxel... | {'Clinical Trial ID': 'NCT01875367', 'Intervention': ['INTERVENTION 1: ', ' Arm A: T-IV + T-SC Vial + T-SC Device', ' Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with vial (Injectable Solution) x 2 cycles, followed by 600mg of T-SC with si... | e5495b51-5f42-4e97-80ec-c215652bd3ab |
Single | Eligibility | NCT00612560 | children and illiterate adults are able to take part in the primary trial, unless they are can read and write in italian. | Contradiction | [
0,
1,
12,
13
] | [] | {'Clinical Trial ID': 'NCT00612560', 'Intervention': ['INTERVENTION 1: ', ' Arm A - Flaxseed & Active Anastrazole', ' 25 mg flaxseed per day and 1 mg anastrozole pill per day', ' Anastrozole: 1 mg per day', ' flaxseed: 25 g per day ground', 'INTERVENTION 2: ', ' Arm B - Flaxseed', ' Flaxseed 25 mg per day and 1 p... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9b6bd158-a66d-42b6-8fe6-843ff05e0c8d | |
Single | Results | NCT00452673 | 1/7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00452673', 'Intervention': ['INTERVENTION 1: ', ' 50 mg Dasatinib + 825 mg/m^2Capecitabine', ' Dose Level 1: 50 milligram (mg) dasatinib oral tablet twice daily (BID) plus 825 mg per meter squared (m^2) capecitabine oral tablet BID. Participants were treated at each dose level (DL) for minim... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9ae51f9c-8544-4764-b731-e4efe9ae0ba6 | |
Single | Adverse Events | NCT00320541 | Cohort 2 of the primary trial recorded three times as many cases of Leukopenia as cohort 1. | Entailment | [
0,
4,
13,
17
] | [] | {'Clinical Trial ID': 'NCT00320541', 'Intervention': ['INTERVENTION 1: ', ' Paclitaxel Plus Bevacizumab (PB)', ' paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 5b1915da-1819-4504-81bd-3f44a83b5e95 | |
Single | Adverse Events | NCT00074152 | Only 2 of the adverse event cases in the primary trial occurred in patients from cohort 1. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [] | {'Clinical Trial ID': 'NCT00074152', 'Intervention': ['INTERVENTION 1: ', ' Arm I', ' Observation (+/- Radiation). Patients receive radiotherapy* within 6 months after surgery.', ' radiation therapy: Given within 6 months after surgery', 'INTERVENTION 2: ', ' Arm II', ' Chemotherapy (+/- Radiation). Within 10 week... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | edb1e4c0-7669-4b8c-878b-ea8ca060c350 | |
Single | Intervention | NCT00429299 | Only one cohort in the primary trial is administered trastuzumab 600 mg/m^2. | Contradiction | [
0,
1,
2,
3,
4,
5,
6
] | [] | {'Clinical Trial ID': 'NCT00429299', 'Intervention': ['INTERVENTION 1: ', ' CT Plus Trastuzumab', ' Participants received chemotherapy (CT), which included paclitaxel 80 milligrams per meters squared (mg/m^2) weekly for 12 weeks, followed by intravenous (IV) fluorouracil 600 mg/m^2, IV epidoxorubicin 75 mg/m^2, and I... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 915939cf-7813-43e7-b503-e14a7eb4e568 | |
Single | Adverse Events | NCT00856492 | Cohort 1 of the primary trial recorded no deaths and no cases of Enterocolitis infectious. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [] | {'Clinical Trial ID': 'NCT00856492', 'Intervention': ['INTERVENTION 1: ', ' Arm 1 (Nab-Paclitaxel + Bevacizumab - AC+PEG-G))', ' Received intravenous (IV) administration of nabpaclitaxel 100 mg/m2 IV weekly for 12 weeks (nP x 12) with IV bevacizumab 10 mg/kg every 2 weeks (six doses), followed by IV doxorubicin 60 mg... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 126c1169-b375-4f89-95b2-52e971d19565 | |
Single | Adverse Events | NCT00284180 | Across all three cohorts of the primary trial a total of two patients had low levels of oxygen in their body tissues. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | [] | {'Clinical Trial ID': 'NCT00284180', 'Intervention': ['INTERVENTION 1: ', ' Vinflunine', ' Vinflunine 320 mg/m2 intravenously day 1 over 20 minutes repeated every 21 days', 'INTERVENTION 2: ', ' Vinflunine/Trastuzumab', ' Vinflunine 280 mg/m2 every 21 days with trastuzumab administered with a loading dose of 8 mg/k... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 11235250-3627-427e-aae9-099507484456 | |
Comparison | Intervention | NCT00236899 | NCT01153672 | the primary trial and the secondary trial both administer Paclitaxel and Gemcitabine to their patients cohorts, but only the secondary trial utilises positron emission tomography. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | {'Clinical Trial ID': 'NCT00236899', 'Intervention': ['INTERVENTION 1: ', ' Treatment Schedule (Weekly)', ' Arm C, Docetaxel and Gemcitabine (Weekly):', ' Docetaxel: 30 mg/m², 30-60 min IV infusion on Days 1, 8, and 15 to be given 30 minutes prior to Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs... | {'Clinical Trial ID': 'NCT01153672', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Enzyme Inhibitor Therapy, AI Sensitization Therapy)', ' Patients receive vorinostat PO QD for 2 weeks followed by AI therapy comprising anastrozole PO QD, letrozole PO QD, OR exemestane PO QD for 6 weeks. Courses repeat every 8 wee... | 8a9f2247-7c51-44be-910b-5091d9abb2ea |
Single | Intervention | NCT00038467 | The patient groups in the primary trial each receive different oral medication, either Tamoxifen or Exemestane. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00038467', 'Intervention': ['INTERVENTION 1: ', ' Exemestane', ' Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 milligram (mg) or 30 mg tablet-in-capsule orally once daily as per standard medical practice, received ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7e283897-4d9e-4353-8331-00f8db16cc7e | |
Comparison | Eligibility | NCT00847171 | NCT01764022 | Male patients with Systemic lupus erythematosus are excluded from the primary trial but may still be eligible for the secondary trial. | Contradiction | [
24,
32
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35
] | {'Clinical Trial ID': 'NCT00847171', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine', ' All patients receive weekly Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed adenocarcinoma of t... | {'Clinical Trial ID': 'NCT01764022', 'Intervention': ['INTERVENTION 1: ', ' BCD-022 (CJSC BIOCAD)', ' BCD-022 is a product code for trastuzumab biosimilar manufactured by CJSC BIOCAD, Russia. In this arm patients will receive 6 courses of treatment with BCD-022 in combination with paclitaxel. Patients will receive BC... | 54b15068-023b-4e60-bb82-2a22512fda62 |
Single | Intervention | NCT00900627 | The two groups in the primary trial receive the same drug treatment, but different doses. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00900627', 'Intervention': ['INTERVENTION 1: ', ' AZD8931 160 mg bd', ' Part A: AZD8931 160mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle', 'INTERVENTION 2: ', ' AZD8931 120 mg bd', ' Part A: AZD8931 120mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 78764961-52be-4235-a2b7-e581497d0099 | |
Comparison | Intervention | NCT03708393 | NCT03456427 | The interventions in the primary trial and the secondary trial require active participation from the patient to apply the treatment. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT03708393', 'Intervention': ['INTERVENTION 1: ', ' IUS Alone', 'IUS alone imaging', 'INTERVENTION 2: ', ' Imagio (IUS+OA)', 'IUS+OA imaging'], 'Eligibility': ['Inclusion Criteria:', ' - Female subjects participating in the PIONEER-0 Study of the Imagio Breast Imaging System with known clinic... | {'Clinical Trial ID': 'NCT03456427', 'Intervention': ['INTERVENTION 1: ', ' All Study Participants: Patient Assisted Compression', ' All subjects will undergo standard of care imaging on one breast. The other breast will be imaged using Patient-Assisted Compression (PAC), followed by Technologist-controlled (TC) Comp... | e09fe98c-ec5c-49cf-9f49-92ba8824e82e |
Single | Intervention | NCT01277757 | the primary trial is not testing a novel Physiotherapy or radiotherapy intervention. | Entailment | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT01277757', 'Intervention': ['INTERVENTION 1: ', ' Akt Inhibitor MK-2206', ' Akt Inhibitor MK-2206 orally once a week on days 1, 8, 15, and 22. Starting dose 200 mg, courses repeat every 28 days.'], 'Eligibility': ['Inclusion Criteria:', ' Patients must have histologically or cytologically c... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a83d98c9-e3da-4449-878b-5fa2f3bee8cf | |
Single | Eligibility | NCT01027416 | To be eligible for the primary trial, patients must have an invasive carcinoma confirmed by core biopsy, and a -ive human chorionic gonadotropin urine test. | Contradiction | [
0,
3,
8
] | [] | {'Clinical Trial ID': 'NCT01027416', 'Intervention': ['INTERVENTION 1: ', ' No Intervention', ' No Intervention: Standard of care', 'INTERVENTION 2: ', ' Tamoxifen', ' Tamoxifen 20 mg orally 1x/day for 4 weeks', ' Tamoxifen: Drug: Tamoxifen 20 mg orally 1x/day for 4 weeks'], 'Eligibility': ['Inclusion Criteria:', ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 41db854e-1565-4eda-8236-550556043b47 | |
Comparison | Adverse Events | NCT00493649 | NCT01201265 | There were no MRSA infections in either the secondary trial or the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | {'Clinical Trial ID': 'NCT00493649', 'Intervention': ['INTERVENTION 1: ', ' TOP2A-amplified Group', ' FISH ratio of TOP2A gene copy number was 2 or greater.', 'INTERVENTION 2: ', ' TOP2A-nonamplified Group', ' FISH ratio of TOP2A gene copy number was less than 2.'], 'Eligibility': ['Inclusion Criteria:', ' A woman... | {'Clinical Trial ID': 'NCT01201265', 'Intervention': ['INTERVENTION 1: ', ' All Participants', ' Participants received a combination therapy of bevacizumab 15 milligram per kilogram (mg/kg) intravenous every 3 weeks with carboplatin recommended dose (area under curve [AUC]= 2) along with gemcitabine 1000 mg/ metre sq... | f559cacb-30e7-47cf-9ac6-5929c1a508f7 |
Comparison | Eligibility | NCT03096847 | NCT01840163 | Female Patients recently prescribed Rapamycin are not eligible for the primary trial, but may be eligible for the secondary trial unless they have a stage 1 to 2 Ductal carcinoma in situ and can speak english. | Contradiction | [
9,
10
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT03096847', 'Intervention': ['INTERVENTION 1: ', ' Ribociclib + Letrozole Cohort A', ' postmenopausal women, or men; naïve.', ' All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.', 'INTERVENTION 2: ', ' Ribociclib + Letrozole Cohort B1', ' premenopausal women ... | {'Clinical Trial ID': 'NCT01840163', 'Intervention': ['INTERVENTION 1: ', ' CanSORT Online Tool (Intervention)', ' Comprehensive (interactive) version of decision tool', ' CanSORT Online Tool', 'INTERVENTION 2: ', ' Static Version of CanSORT Tool (Control)', ' Static version (non-interactive) version of CanSORT de... | 79362f6d-ef2c-4b93-8719-be361d0b5acc |
Comparison | Eligibility | NCT02650193 | NCT00656669 | Patients with Class III obesity cannot be included in the primary trial, but can be entered into the secondary trial, even if they have uncontrolled Hypertension. | Contradiction | [
0,
15
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18
] | {'Clinical Trial ID': 'NCT02650193', 'Intervention': ['INTERVENTION 1: ', ' Cycle 0: HSP-130 3mg', ' Participants who had not received background chemotherapy treatment in the study were administered a single dose of 3 mg of HSP-130 SC at Day 1 of Cycle 0. Participants were followed approximately 30 days after last d... | {'Clinical Trial ID': 'NCT00656669', 'Intervention': ['INTERVENTION 1: ', ' Sunitinib Monotherapy', ' Patients who completed the Sunitinib monotherapy segment'], 'Eligibility': ['Inclusion Criteria:', ' Patients must have histologically-confirmed adenocarcinoma of the breast with operable or inoperable stage 1c (pri... | 54918996-1b4d-48bd-a0ca-13d8e259767b |
Comparison | Adverse Events | NCT00679341 | NCT00201851 | Patients in the secondary trial and those in the primary trial did not share any of the same adverse events. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00679341', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine', ' Patients received trastuzumab emtansine 3.6 mg/kg intravenously (IV) administered over 30-90 minutes every 3 weeks on Day 1 of each 21-day cycle.', 'INTERVENTION 2: ', ' Trastuzumab + Docetaxel', ' Patients receive... | {'Clinical Trial ID': 'NCT00201851', 'Intervention': ['INTERVENTION 1: ', ' A - Scheduled Surgery', ' Patient scheduled for mid-luteal phase surgical oophorectomy/mastectomy plus Tamoxifen', ' Tamoxifen: 20 mg po daily x 5 years', ' Surgery: Oophorectomy: Group A-Surgical oophorectomy and mastectomy in estimated 5 ... | a5a1c7f1-92f4-4436-9dcb-ab222ff1c8a5 |
Single | Adverse Events | NCT02015676 | There are no recorded cases of thrombocytopenia in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [] | {'Clinical Trial ID': 'NCT02015676', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab, Doxorubicin, Paclitaxel; Phase II', ' Participants received an initial loading dose of trastuzumab 4 mg/kg, IV, over 1.5 hours on Day 1 (Week 1), followed by 2 mg/kg, IV, over 30 minutes once per week from Week 2 to Week 52 or un... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 52c8361f-75dc-45f1-a35c-79180a22b931 | |
Single | Results | NCT01091168 | Patients in the control group of the primary trial had a median Overall Survival of less than a year, however several patients in arm B survived longer than a year. | Contradiction | [
0,
1,
2,
3,
11,
12,
13,
14,
15,
9,
17
] | [] | {'Clinical Trial ID': 'NCT01091168', 'Intervention': ['INTERVENTION 1: ', ' Vinflunine', ' Patients randomised in the test arm (arm A) received VFL at the dose of 280 mg/m² on day 1 of each cycle every 3 weeks, over a 20-minute intravenous (IV) infusion. Cycles were repeated every 3 weeks.', ' vinflunine: 280 mg/m2 ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f2f05760-cc22-4fe8-a24f-f6d43f9c9a86 | |
Single | Results | NCT01271725 | In the primary trial The Percentage of Participants With Objective Response (OR) for the Afatinib Monotherapy was 18% lower than the Afatinib and Paclitaxel or Vinorelbine Combination Therapy group. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01271725', 'Intervention': ['INTERVENTION 1: ', ' Afatinib Monotherapy', ' Patient received Afatinib monotherapy orally once daily at a dose of 40 milligram (mg) film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal. Pati... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | db8ffa86-bf52-47bb-89f7-42e7ae47b84d | |
Single | Intervention | NCT02392611 | the primary trial cohorts are not seperated based on patient characteristics. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT02392611', 'Intervention': ['INTERVENTION 1: ', ' Monotherapy: Alobresib 0.6 mg', ' Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy, or for whom no standard therapy existed received alobresib tablets at a dose of 0.6 mg orally once ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 5a01d00f-8601-4c17-b814-be87e63b0d8a | |
Single | Eligibility | NCT01351376 | Patients currently prescribed laxatives are not excluded from the primary trial. | Contradiction | [
5,
18
] | [] | {'Clinical Trial ID': 'NCT01351376', 'Intervention': ['INTERVENTION 1: ', ' Placebo', ' CDT + inactive LLL', ' Low Level Laser Therapy: Placebo LLL combined with CDT', 'INTERVENTION 2: ', ' LLL Combined With CDT', ' CDT + active LLL', ' Low Level Laser: Active LLL combined with CDT'], 'Eligibility': ['Inclusion C... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7577f05f-04e9-44de-9e00-b7411ff4010f | |
Single | Adverse Events | NCT00191451 | Patients in the primary trial experienced a only one type of Oesophageal adverse events and several types of cardiac adverse events. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [] | {'Clinical Trial ID': 'NCT00191451', 'Intervention': ['INTERVENTION 1: ', ' HER2+', ' Human Epidermal growth factor Receptor 2 positive: Gemcitabine + Carboplatin + Herceptin.', ' Gemcitabine: Day 1 of 14 day cycle (Cycles 1-9):1500 milligram per square meter (mg/m2) intravenous (IV) (30 minute infusion); Carboplati... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 3b0440e6-cf85-4236-8a1d-2e3572143946 | |
Single | Eligibility | NCT00077857 | Patients must be older than 18, female, have one or more target lesions and more than 2 regiments of chemotherapy to participate in the primary trial. | Entailment | [
0,
1,
2,
5
] | [] | {'Clinical Trial ID': 'NCT00077857', 'Intervention': ['INTERVENTION 1: ', ' 1250 mg/m^2 Capecitabine + Docetaxel', ' 1250 mg/m^2 capecitabine (Xeloda®) orally twice a day on days 1 to 14 of each 3 week cycle, in combination with docetaxel (Taxotere®) 75 mg/m^2 intravenous on day 1 of each 3 week cycle.', 'INTERVENTIO... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6f342205-ef33-482a-b74a-74644537538b | |
Single | Results | NCT00950742 | 100 participants in the Afatinib 20mg + Herceptin group of the primary trial suffer Dose Limiting Toxicities. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00950742', 'Intervention': ['INTERVENTION 1: ', ' Afatinib 20mg + Herceptin', ' Patients received continuous daily dosing with Afatinib 20mg film-coated tablets and once weekly an intravenous infusion of Herceptin until disease progression or lack of clinical benefit. This group includes pat... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 5b63fffb-0a75-414f-8744-5fea78395f28 | |
Comparison | Eligibility | NCT02279108 | NCT00943670 | Adult Patients with Histologically proven HER2- infiltrating breast cancer that have had a Previous lumpectomy or same side mammary reduction are excluded from both the secondary trial and the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19
] | {'Clinical Trial ID': 'NCT02279108', 'Intervention': ['INTERVENTION 1: ', ' Double Detection Indocyanine + Isotope', ' intradermal injection of 2.5 milligrams of indocyanine green and 20 MBq of technetium 99 before breast surgery', ' indocyanine green: One injection, 2.5 milligrams per patient, intradermal use', ' ... | {'Clinical Trial ID': 'NCT00943670', 'Intervention': ['INTERVENTION 1: ', ' T-DM1', ' Trastuzumab emtansine (T-DM1) was administered to participants by intravenous (IV) infusion on Day 1 of every 3 week cycle at a dose of 3.6 mg/kg.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically documented, locally advan... | 9e655973-7d1d-4528-8394-a9cbcf0b978f |
Comparison | Intervention | NCT00073073 | NCT00054028 | There is no placebo or control group in the primary trial, in the secondary trial, Suramin acts as placebo. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT00073073', 'Intervention': ['INTERVENTION 1: ', ' Exemestane', ' exemestane 25 mg by mouth (PO) every day for two years taken with calcium carbonate 1200 mg PO every day and vitamin D 400 IU PO every day Initially patients were initially planned to receive Celecoxib but the study was amended... | {'Clinical Trial ID': 'NCT00054028', 'Intervention': ['INTERVENTION 1: ', ' Suramin and Paclitaxel', ' Suramin will be infused weekly over 30 minutes. Four hours after the completion of the suramin infusion the 1 hour infusion of paclitaxel will begin.'], 'Eligibility': ['Inclusion Criteria:', ' Patients must have h... | ea62355f-aab9-4796-8658-746c0b669ca7 |
Single | Adverse Events | NCT00454805 | In the primary trial there were more cases of Intestinal Obstruction in cohort 1 than in cohort 2. | Contradiction | [
0,
8,
14,
22
] | [] | {'Clinical Trial ID': 'NCT00454805', 'Intervention': ['INTERVENTION 1: ', ' Cediranib 45 mg', ' Cediranib 45 mg+Fulvestrant 250 mg', ' Patients randomised to the investigational arm (fulvestrant + cediranib) received treatment according to the following schedule:', ' Day 1: fulvestrant 500 mg im', ' Day 15: fulves... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 55eaae8d-611c-4dbb-b162-de664902e059 | |
Comparison | Intervention | NCT00485953 | NCT00068601 | the cyclophosphamide dose in the secondary trial and the Placebo dose in the primary trial are not specified. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | {'Clinical Trial ID': 'NCT00485953', 'Intervention': ['INTERVENTION 1: ', ' Active Medicine Group', ' risedronate 35 mg weekly', 'INTERVENTION 2: ', ' Placebo Group', ' Received placebo medication once weekly'], 'Eligibility': ['Inclusion Criteria:', ' elderly postmenopausal women (ages 55 and older)', ' osteopen... | {'Clinical Trial ID': 'NCT00068601', 'Intervention': ['INTERVENTION 1: ', ' Standard Chemotherapy', ' Patients receive cyclophosphamide-containing chemotherapy alone.', ' cyclophosphamide: Part of planned chemotherapy regimen', 'INTERVENTION 2: ', ' Chemotherapy Plus Goserelin', ' Patients receive goserelin subcut... | c3438bb2-4a49-4f14-ae50-a46fb48d0208 |
Single | Intervention | NCT00821964 | the primary trial participants apply topical imiquimod to cutaneous lesions once daily on days for a total of 13 days every 28 day cycle. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7
] | [] | {'Clinical Trial ID': 'NCT00821964', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Biological Therapy, Chemo)', ' Patients receive Abraxane IV over 30 minutes on days 1, 8, and 15 and apply topical imiquimod to cutaneous lesions QD on days 1-4, 8-11, 15-18, and 22-25. Treatment repeats every 28 days for up to 3 c... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8f505cec-6ad4-4142-a861-1771e3ae5cdd | |
Single | Eligibility | NCT00478257 | Adequate Hematologic, Hepatic and renal function is not necessary for participating in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [] | {'Clinical Trial ID': 'NCT00478257', 'Intervention': ['INTERVENTION 1: ', ' Effect of Bright Light', ' Effect of bright light on fatigue in women with breast cancer', 'INTERVENTION 2: ', ' Effect of Red Light', ' effect of red light on fatigue in women with breast cancer'], 'Eligibility': ['Inclusion Criteria:', ' ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8f4f9793-041d-448b-9da8-b0c787a875bb | |
Comparison | Intervention | NCT01735175 | NCT01216319 | the secondary trial is testing a surgical intervention, unlike the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT01735175', 'Intervention': ['INTERVENTION 1: ', ' LA-EP2006', ' During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application.', ' LA-EP2006: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemothe... | {'Clinical Trial ID': 'NCT01216319', 'Intervention': ['INTERVENTION 1: ', ' Nipple Reconstruction Cylinder', ' Nipple reconstruction: Biodesign® Nipple Reconstruction Cylinder'], 'Eligibility': ['Inclusion Criteria:', ' Patient presents with a history of breast cancer, having previously completed either uni- or bi-l... | d13e5689-2a9e-4295-b3f8-e4a18fe42bf1 |
Single | Intervention | NCT00376597 | the primary trial do not receive any intervention by IV, orally or by surgery during the study. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00376597', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Lymphedema Education)', ' Six weeks after surgery, patients receive a brief initial post-operative care session describing lymphedema risk and prevention through oral instruction and written materials. Patients complete physical assess... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 61d56c2a-089f-4fa3-9e97-3a9007576077 | |
Single | Eligibility | NCT00411788 | If Hannah has been taking ketoconazole to treat athlete's foot for 6 weeks, until today, she will not be eligible for the primary trial for the next month. | Entailment | [
18,
33
] | [] | {'Clinical Trial ID': 'NCT00411788', 'Intervention': ['INTERVENTION 1: ', ' Sirolimus and Trastuzumab', ' Patients received oral sirolimus 6 mg daily in combination with weekly trastuzumab administered intravenously with a loading dose of 4 mg/kg followed by 2 mg/kg weekly in a 28-day cycle. A subsequent amendment al... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 5b90b8de-97b9-4ed7-b5a4-e3724fd38c41 | |
Comparison | Intervention | NCT01712009 | NCT00343382 | Cohort 2 patients in the primary trial receive naproxen at the same frequency and dosage as cohort 2 patients in the secondary trial receive Pilocarpine. | Contradiction | [
3,
4,
5
] | [
3,
4,
5
] | {'Clinical Trial ID': 'NCT01712009', 'Intervention': ['INTERVENTION 1: ', ' No Prophylaxis', ' Participants received adjuvant or neoadjuvant chemotherapy and pegfilgrastim.', 'INTERVENTION 2: ', ' Naproxen 500 mg BID', ' Participants received adjuvant or neoadjuvant chemotherapy and pegfilgrastim in addition to pro... | {'Clinical Trial ID': 'NCT00343382', 'Intervention': ['INTERVENTION 1: ', ' Collective Placebo', ' Patients receive 1 capsule of placebo 2 times per day for 6 weeks and; patients receive 1 capsule of placebo 4 times per day for 6 weeks.', 'INTERVENTION 2: ', ' Pilocarpine 2 Times Per Day', ' Patients receive 5mg of... | bad4d3e7-a05a-44fd-937a-c94a23655c03 |
Comparison | Adverse Events | NCT00499122 | NCT00454805 | There were several cases of Multi-Organ Failure in both cohort 1 of the secondary trial and cohort 2 of the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | {'Clinical Trial ID': 'NCT00499122', 'Intervention': ['INTERVENTION 1: ', ' NOV-002 and Chemotherapy', ' NOV-002:', ' Cycle 1, Day -1 only: 60 mg intravenously (IV) x 2, 3 hours (+/- 30 minutes) apart', ' Cycles 1 - 8, Day 1: 60 mg IV, 1 hour (+/- 30 minutes) prior to chemotherapy administration', ' Cycle 1 - 8, D... | {'Clinical Trial ID': 'NCT00454805', 'Intervention': ['INTERVENTION 1: ', ' Cediranib 45 mg', ' Cediranib 45 mg+Fulvestrant 250 mg', ' Patients randomised to the investigational arm (fulvestrant + cediranib) received treatment according to the following schedule:', ' Day 1: fulvestrant 500 mg im', ' Day 15: fulves... | b88eaf78-957d-4b3d-bcb2-d029b7d7b7e2 |
Single | Adverse Events | NCT00191789 | In the primary trial there was 1 case of jaundice. | Entailment | [
0,
12
] | [] | {'Clinical Trial ID': 'NCT00191789', 'Intervention': ['INTERVENTION 1: ', ' Gemcitabine+Doxorubicin+Cisplatin+Surgery', ' Gemcitabine: 1200 mg/m^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8).', ' Doxorubicin: 60 mg/m^2, IV, eve... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0c435231-a09c-4424-924a-13840c6b7068 | |
Comparison | Eligibility | NCT01217385 | NCT01202591 | Prior exposure to exemestane is not allowed for patients in the secondary trial, however, the primary trial may accept patients despite this. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [
6,
7
] | {'Clinical Trial ID': 'NCT01217385', 'Intervention': ['INTERVENTION 1: ', ' Diffuse Optical Spectroscopy Imaging (DOSI', ' Participants undergo approximately four assessments of breast health using the DOSI technology during treatment and prior to surgery for breast cancer.', ' DOSI: Bedside DOSI images of the tissu... | {'Clinical Trial ID': 'NCT01202591', 'Intervention': ['INTERVENTION 1: ', ' AZD4547 80mg bd Cont + Ex 25mg', ' 80 mg AZD4547 BD continuous + 25 mg exemestane', 'INTERVENTION 2: ', ' AZD4547 40mg Cont + Ex 25mg', ' 40 mg AZD4547 BD continuous + 25 mg exemestane'], 'Eligibility': ['Inclusion Criteria:', ' Post-menop... | 0812dcc1-eab5-4d5f-9d51-934f9b1f05ca |
Comparison | Adverse Events | NCT01252290 | NCT00479674 | Unlike the secondary trial, the primary trial does not record any instances of Anemia, Dyspepsia, Nausea or depression. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | {'Clinical Trial ID': 'NCT01252290', 'Intervention': ['INTERVENTION 1: ', ' Lovaza™', ' Lovaza™: 4 capsules daily for 6 months'], 'Eligibility': ['Inclusion Criteria', ' Subjects must be postmenopausal and between the ages of 25 and 69 years. Menopause is defined by no menstrual period for more than one year and int... | {'Clinical Trial ID': 'NCT00479674', 'Intervention': ['INTERVENTION 1: ', ' Abraxane, Carboplatin, Bevacizumab', ' Abraxane 100 mg/m2 IV over 30 min days 1,8,15.; Carboplatin AUC=2 IV over 15 min days 1,8,15., Bevacizumab 10 mg/kg IV days 1,15', ' Abraxane: 100 mg/m2 IV over 30 min days 1,8,15. Cycles Repeated Every... | a29e6a86-65f3-4565-93e2-81f49fa837e4 |
Single | Eligibility | NCT00418457 | Scheduled flap reconstruction within 10 days prior to beginning is acceptable for patients entering the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | [] | {'Clinical Trial ID': 'NCT00418457', 'Intervention': ['INTERVENTION 1: ', ' General Anesthesia and Opioid', ' General anesthesia followed by opioid administration', ' General anesthesia and opioids: General anesthesia, usually with sevoflurane, and opioid analgesia', 'INTERVENTION 2: ', ' Regional Analgesia and Pro... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2470d8d1-27cd-41a5-9e5d-f62d4bbdd049 | |
Comparison | Eligibility | NCT03190083 | NCT01805089 | All cancer stages are accepted for the primary trial and the secondary trial. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT03190083', 'Intervention': ['INTERVENTION 1: ', ' 3-dimensional Tomosynthesis Mammogram', ' The patients assigned a Breast imaging-reporting and data system (BIRADS) 5 category at the time of diagnosis and all new diagnosed breast cancer patients, will undergo a separate 2-D plus DBT in addi... | {'Clinical Trial ID': 'NCT01805089', 'Intervention': ['INTERVENTION 1: ', ' Melatonin', ' Taken orally, once per day, at/around 9:00pm', 'Melatonin', 'INTERVENTION 2: ', ' Placebo', ' Taken orally, once per day, at/around 9:00pm', 'Placebo'], 'Eligibility': ['Inclusion Criteria:', ' History of ductal carcinoma in ... | 34bb7f09-3b2b-464f-96df-c8d80b1206fc |
Single | Adverse Events | NCT00357110 | Less than 20% of patients in cohort 1 of the primary trial had Varicose Veins. | Entailment | [
0,
6
] | [] | {'Clinical Trial ID': 'NCT00357110', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant + Anastrozole', ' fulvestrant 500 mg + anastrozole 1 mg', 'INTERVENTION 2: ', ' Anastrozole', 'anastrozole 1 mg'], 'Eligibility': ['Inclusion Criteria:', ' Postmenopausal women with hormone receptor-positive early breast cancer ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e9824c27-bb70-4707-9599-ff20281f873e | |
Comparison | Results | NCT00320385 | NCT00075270 | The median time from randomization until the first documented sign of disease progression or death due to any cause for all participants in the primary trial, was lower than the median time for patients in the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | {'Clinical Trial ID': 'NCT00320385', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab + Lapatinib', ' Participants received Lapatinib 1000 milligram (mg) tablets orally daily 1 hour before or after breakfast along with Trastuzumab infusion at a loading dose of 4 milligrams/kilogram (mg/kg) body weight intravenously... | {'Clinical Trial ID': 'NCT00075270', 'Intervention': ['INTERVENTION 1: ', ' Lapatinib With Paclitaxel', ' Participants received lapatinib 1500 milligrams (mg) orally once daily (OD) with paclitaxel 175 mg/meters squared (m^2) intravenously (IV) over the course of 3 hours, every 3 weeks. The treatment group was strati... | 43fcba9b-4edd-433d-86a7-370cbbf56853 |
Single | Results | NCT02555657 | The Median time from randomization to death due to any cause was higher in cohort 1 of the primary trial, compared to cohort 2. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT02555657', 'Intervention': ['INTERVENTION 1: ', ' Pembrolizumab', ' Participants received pembrolizumab 200 mg IV every Q3W for up to 35 administrations (up to ~2 years).', 'INTERVENTION 2: ', ' Chemotherapy', " Participants received capecitabine, eribulin, gemcitabine, or vinorelbine as s... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 196c7a35-58a0-4d2d-a0a6-e9e3de077fb1 | |
Single | Adverse Events | NCT00398567 | 3/4 patients in the primary trial did not suffer any adverse events. | Entailment | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT00398567', 'Intervention': ['INTERVENTION 1: ', ' Part 2 - Expanded MTD Cohort', ' All subjects receiving HKI-272 (neratinib) in combination with trastuzumab (Herceptin) HKI-272: neratinib 240 mg daily by mouth Herceptin: Herceptin 4 mg/kg IV as a loading dose followed by Herceptin 2 mg/kg w... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 27e0b995-b3d1-46a6-900a-d6e513504ff3 | |
Comparison | Intervention | NCT01727011 | NCT01420146 | the primary trial and the secondary trial interventions involve a variety of scans, such as CT, PET and dosimetry | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT01727011', 'Intervention': ['INTERVENTION 1: ', ' IPAS', ' Once the patient recorded in the trial, and after completion of a post-implant dosimetry scanner to analyze the dose distribution within the target volume and organs at risk, the patient is treated by irradiation and partial accelera... | {'Clinical Trial ID': 'NCT01420146', 'Intervention': ['INTERVENTION 1: ', ' Zr89-trastuzumab PET/CT', ' Zr89-trastuzumab (trastuzumab labelled with zirconium 89) for PET/CT single arm'], 'Eligibility': ['Inclusion criteria:', ' All patients selected for this imaging study are patients scheduled to start trastuzumab-... | 36a5357f-0c5f-4c64-a56a-a84aab165a16 |
Single | Adverse Events | NCT00024102 | A patient in cohort 2 of the primary trial received a Packed red blood cell transfusion. | Entailment | [
12,
18
] | [] | {'Clinical Trial ID': 'NCT00024102', 'Intervention': ['INTERVENTION 1: ', ' Standard Chemotherapy', ' Patient/Physician choice of:', ' CMF: cyclophosphamide (100 mg/m^2 orally days 1-14)+ MTX (40 mg/m^2 by IV days 1 and 8) + 5-FU (600 mg/m^2 by IV days 1 and 8) repeated every 28 days for 6 cycles OR', ' AC: Cycloph... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c876167f-fe1e-4c3b-9183-dd3c1069ed0b | |
Single | Results | NCT00191152 | The longest Time to Disease Progression the primary trial was over 11 months in the Docetaxel Plus Capecitabine group. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16
] | [] | {'Clinical Trial ID': 'NCT00191152', 'Intervention': ['INTERVENTION 1: ', ' Gemcitabine Plus Docetaxel', ' gemcitabine 1000 milligrams per meter squared (mg/m2) intravenous, days 1 and 8 every 21 days plus docetaxel 75 mg/m2, intravenous, day 1 every 21 days.', ' Treatment continues until progression of disease at w... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d6989b67-ae99-4c2a-a67d-c2285cc57058 | |
Comparison | Results | NCT00320385 | NCT00075270 | Both cohorts in the primary trial outperformed cohort 1 of the secondary trial in median PFS. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | {'Clinical Trial ID': 'NCT00320385', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab + Lapatinib', ' Participants received Lapatinib 1000 milligram (mg) tablets orally daily 1 hour before or after breakfast along with Trastuzumab infusion at a loading dose of 4 milligrams/kilogram (mg/kg) body weight intravenously... | {'Clinical Trial ID': 'NCT00075270', 'Intervention': ['INTERVENTION 1: ', ' Lapatinib With Paclitaxel', ' Participants received lapatinib 1500 milligrams (mg) orally once daily (OD) with paclitaxel 175 mg/meters squared (m^2) intravenously (IV) over the course of 3 hours, every 3 weeks. The treatment group was strati... | 90dfb0bd-e0a0-47a9-945b-fd8ec8faaaa1 |
Single | Results | NCT00076024 | The minimum period of time from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in the primary trial, was just over a year. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00076024', 'Intervention': ['INTERVENTION 1: ', ' Axitinib + Docetaxel (Phase 2, Double-blind)', ' Axitinib (AG-013736) 5 mg tablet orally BID starting from Day 1 of Cycle 1, in cycles of 3 weeks. Docetaxel 80 mg/m^2 1 hr IV infusion on Day 1 of each cycle, in cycles of 3 weeks. Treatment wa... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 886d3280-bc44-4a58-a5ba-66b018210332 | |
Comparison | Adverse Events | NCT00323479 | NCT03078751 | There were more cases of deteriorating mental health in the primary trial than the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | {'Clinical Trial ID': 'NCT00323479', 'Intervention': ['INTERVENTION 1: ', ' Anastrozole 1 mg', ' Anastrozole 1 mg once daily'], 'Eligibility': ['Inclusion Criteria:', ' Post menopausal woman with a breast cancer and scheduled for an adjuvant treatment with anastrozole', ' WHO performance status 0, 1 or 2', ' Provi... | {'Clinical Trial ID': 'NCT03078751', 'Intervention': ['INTERVENTION 1: ', ' Ribociclib + Adjuvant Endocrine Therapy (ET)', ' Patients in this arm took Ribociclib in combination with standard adjuvant endocrine therapy. ET was one of these 4: Letrozole, Anastrozole, Exemestane, Tamoxifen (Tamoxifen no longer permitted... | 03dcb6d9-efae-40ec-87ee-68ef89424498 |
Single | Adverse Events | NCT00193206 | the primary trial records a total of 7 patients suffering from various infections. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT00193206', 'Intervention': ['INTERVENTION 1: ', ' Intervention', ' Systemic Therapy', ' ABI-007 : ABI-007 175 mg/m2 D1 q 14 days x 6 cycles', ' Epirubicin : Epirubicin 50 mg/m2 D1 q 14 days x 6 cycles', ' Gemcitabine : Gemcitabine 2000 mg/m2 IV D1 q 14 days x 6 cycles'], 'Eligibility': ['... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b881b717-1c8a-41b8-9554-6ed9e8ee7c77 | |
Single | Adverse Events | NCT01439282 | In total cohort 1 of the primary trial recorded 20% more adverse events than cohort 2. | Contradiction | [
0,
1,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01439282', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1: Eribulin Mesylate Plus 900 mg/m^2 Capecitabine', ' Eribulin mesylate (1.4 mg/m^2) was injected directly as an IV infusion over 2 to 5 minutes on Day 1 and Day 8 of the 21-day cycle for a total of 4 cycles. Alternatively, eribulin me... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 20530faf-addb-47bf-896d-b9666e149223 | |
Comparison | Eligibility | NCT00041067 | NCT01273896 | Patients with ER positive, PR positive or HER2 positive stage 4 tumors may be eligible for the secondary trial or the primary trial. | Contradiction | [
0,
1
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35,
36,
37,
38,
39,
40,
41,
42
] | {'Clinical Trial ID': 'NCT00041067', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab, Docetaxel, Vinorelbine and Filgrastim', ' Trastuzumab, docetaxel, vinorelbine and filgrastim', ' docetaxel : 60 mg/m^2 on Day 1 of 21-day cycles', ' vinorelbine : 27.5 mg/m^2 on Days 8 and 15', ' filgrastim : 5 microg/kg/day o... | {'Clinical Trial ID': 'NCT01273896', 'Intervention': ['INTERVENTION 1: ', ' STA-9090', ' This will be a monotherapy, open-label phase 2 study of STA-9090 in patients who have metastatic breast cancer.', ' STA-9090: All patients will receive 200 mg/m2 of STA-9090 once weekly by a 1-hour IV infusion for three consecut... | 52557c9f-f771-4f31-bb71-01f87f9f5821 |
Single | Results | NCT00373256 | Cohort 1 of the primary trial included over 200 patients being treated with Sunitinib and Paclitaxel for a duration of 18 months or until death, and the median PFS for this group was just under 7 and a half months. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00373256', 'Intervention': ['INTERVENTION 1: ', ' Sunitinib + Paclitaxel', ' Starting sunitinib doses of 25 mg daily. After Cycle 1, escalation to 37.5 mg daily was permitted in the absence of complicated neutropenia and if all 3 Cycle 1 paclitaxel doses were successfully administered at 90 ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 11472413-533f-45f9-9aac-c46bca318aab | |
Single | Eligibility | NCT00191854 | Patients do not need to have a Her2neu positive tumours or a measurable indicator lesion to be included in the primary trial | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT00191854', 'Intervention': ['INTERVENTION 1: ', ' Gemcitabine + Paclitaxel', ' Gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles.', ' Paclitaxel: 150 mg/m2, IV, every 14 days x 8 cycles', 'INTERVENTION 2: ', ' Gemcitabine + Carboplatin', ' G... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 3b8f5ef2-b0bb-42e8-a165-45a2d35780e0 | |
Comparison | Intervention | NCT00880022 | NCT00916578 | Only patients in cohort 2 of the primary trial undergo Trunk compression. However all patients in the secondary trial are treated with Trunk compression. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT00880022', 'Intervention': ['INTERVENTION 1: ', ' Arm Compression Only', '[Not Specified]', 'INTERVENTION 2: ', ' Arm, Trunck and Chest Compression', '[Not Specified]'], 'Eligibility': ['Inclusion Criteria:', ' Individuals at least six months post- surgery and/or radiation treatment for bre... | {'Clinical Trial ID': 'NCT00916578', 'Intervention': ['INTERVENTION 1: ', ' Single Arm Institution, Open Label, Phase II', ' Patients will received 825 mg/m2 bid of capecitabine. One of the two daily doses of capecitabine will be taken 2 hours before receiving radiotherapy. Capecitabine will be administered when pati... | 6446f085-c6b0-43ce-82ed-16d6952b549e |
Single | Intervention | NCT01104584 | the primary trial participants receive either 50mg/m2 trastuzumab, Tamoxifen or Exemestane. | Contradiction | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT01104584', 'Intervention': ['INTERVENTION 1: ', ' CMRM Versus UMRM', '[Not Specified]'], 'Eligibility': ['Inclusion Criteria:', ' Recent histologically proven diagnosis of breast cancer after having obtained X-Ray Mammography (XRM) of both breasts (according to American College of Radiology ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7348c2e8-9eb5-4ed6-9a5d-bcb02a5c3a0a | |
Comparison | Adverse Events | NCT00110084 | NCT01961544 | the primary trial and the secondary trial both reported cases of sepsis in their patients. | Entailment | [
0,
10
] | [
0,
12
] | {'Clinical Trial ID': 'NCT00110084', 'Intervention': ['INTERVENTION 1: ', ' Nab-paclitaxel/Gemcitabine', ' Nab (nanoparticle albumin-bound)-Paclitaxel (125mg/m^2)(IV over 30 min) (days 1 and 8) on 21 day cycle and gemcitabine (1000 mg/m^2)(IV over 30 min) (days 1 and 8) on 21 day cycle'], 'Eligibility': ['DISEASE CHA... | {'Clinical Trial ID': 'NCT01961544', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate 1.4 mg/m^2', ' Participants received 1.4 milligrams per meters squared (mg/m^2) eribulin mesylate intravenously over the course of 2 to 5 minutes on Day 1 and Day 8 of each 21-day cycle.'], 'Eligibility': ['Inclusion Criteri... | db90c9d8-b289-48e2-a7df-f41620b3feab |
Single | Adverse Events | NCT01419197 | There are no cases of agranulocytosis in the primary trial. | Entailment | [
0,
4
] | [] | {'Clinical Trial ID': 'NCT01419197', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine', ' Trastuzumab emtansine 3.6 mg/kg intravenously every 3 weeks until disease progression (as assessed by the investigator) or unmanageable toxicity.', 'INTERVENTION 2: ', " Treatment of Physician's Choice", " Treatmen... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f2533676-1e72-444e-8aef-1fa826ceb804 | |
Comparison | Intervention | NCT03708393 | NCT03456427 | The intervention in the primary trial is carried out by either a doctor, radiographer or a sonographer, whereas one of the interventions in the secondary trial requires active participation from the patient. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT03708393', 'Intervention': ['INTERVENTION 1: ', ' IUS Alone', 'IUS alone imaging', 'INTERVENTION 2: ', ' Imagio (IUS+OA)', 'IUS+OA imaging'], 'Eligibility': ['Inclusion Criteria:', ' - Female subjects participating in the PIONEER-0 Study of the Imagio Breast Imaging System with known clinic... | {'Clinical Trial ID': 'NCT03456427', 'Intervention': ['INTERVENTION 1: ', ' All Study Participants: Patient Assisted Compression', ' All subjects will undergo standard of care imaging on one breast. The other breast will be imaged using Patient-Assisted Compression (PAC), followed by Technologist-controlled (TC) Comp... | c15309b3-eb08-4d46-94ef-e4a504a111db |
Comparison | Eligibility | NCT02964234 | NCT00246090 | Patients eligible for the primary trial and the secondary trial must live in the USA. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29
] | {'Clinical Trial ID': 'NCT02964234', 'Intervention': ['INTERVENTION 1: ', ' Empowerment', ' Behavior: Empowerment', ' Empowerment: Three group sessions (breast cancer education; communication; volunteerism) 1.5 hours 3 times across 3 weeks', 'INTERVENTION 2: ', ' Education', ' Behavior: Education', ' Education: T... | {'Clinical Trial ID': 'NCT00246090', 'Intervention': ['INTERVENTION 1: ', ' E7389 1.4 mg/m^2', ' E7389 1.4 mg/m^2 intravenous bolus given over 2-5 minutes on Days 1 and 8 every 21 days.'], 'Eligibility': ['Inclusion Criteria:', ' Female patients with histologically or cytologically confirmed carcinoma of the breast.... | 4885cd77-628c-4b8f-8345-6bce2165938c |
Single | Adverse Events | NCT00759785 | Only one adverse event, a Breast abscess, is observed in patients from cohort 1 of the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00759785', 'Intervention': ['INTERVENTION 1: ', ' ER-positive Luminal B (ER+)', ' ER-positive Luminal B participants received a single dose of dalotuzumab 20 mg/kg infused over 60-120 minutes.', 'INTERVENTION 2: ', ' Triple Negative (TN)', ' Triple Negative participants received a single d... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8809cc5e-36d5-4f7e-b06d-b1915a421f71 | |
Comparison | Eligibility | NCT00908791 | NCT00297596 | Female patients over the age of 60, with Histologically confirmed breast cancer and advanced Alzheimer's disease are ineligible for both the secondary trial and the primary trial, unless they have an ECOG>2. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [
0,
21
] | {'Clinical Trial ID': 'NCT00908791', 'Intervention': ['INTERVENTION 1: ', ' Pre CLA', ' Women with histologically proven invasive non-metastatic breast cancer.', 'INTERVENTION 2: ', ' Post CLA', ' Women with histologically proven invasive non-metastatic breast cancer.'], 'Eligibility': ['Inclusion Criteria:', ' Al... | {'Clinical Trial ID': 'NCT00297596', 'Intervention': ['INTERVENTION 1: ', ' Oxaliplatin/Trastuzumab', ' Patients with HER2 positive breast cancer received treatment with oxaliplatin 130 mg/m2 IV day 1 and trastuzumab 6 mg/kg (following 8 mg/kg loading dose during cycle 1). Cycles were repeated every 21 days. Oxalipla... | f0f7241c-0c2d-47cb-8b42-6e5d7494b2b1 |
Comparison | Adverse Events | NCT00623233 | NCT01525589 | More patients with a Low Platelet Count where found in the primary trial than in the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | {'Clinical Trial ID': 'NCT00623233', 'Intervention': ['INTERVENTION 1: ', ' Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg', ' Gemcitabine 2500 milligrams per square meter (mg/m^2) intravenous (IV) over 30 minutes given on Day 1 every 14 days (q 14 days) until disease progression (PD) or unacceptable toxicity.', ' B... | {'Clinical Trial ID': 'NCT01525589', 'Intervention': ['INTERVENTION 1: ', ' Cohort A (BRCA+)', ' Patients with known deleterious BRCA1/2 mutation status at study entry', 'INTERVENTION 2: ', ' Cohort A1 (BRCA+/PARPi)', ' Patients with known deleterious BRCA1/2 mutation status and prior treatment with PARPi.'], 'Elig... | ca27db58-14c4-4889-95b1-69be9c10a07a |
Single | Eligibility | NCT03190083 | All cancer stages are accepted for the primary trial. | Entailment | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT03190083', 'Intervention': ['INTERVENTION 1: ', ' 3-dimensional Tomosynthesis Mammogram', ' The patients assigned a Breast imaging-reporting and data system (BIRADS) 5 category at the time of diagnosis and all new diagnosed breast cancer patients, will undergo a separate 2-D plus DBT in addi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 5147b171-b5dc-46d6-a153-1a6d9a062ef1 | |
Single | Adverse Events | NCT00656669 | the primary trial did not record any adverse events. | Entailment | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT00656669', 'Intervention': ['INTERVENTION 1: ', ' Sunitinib Monotherapy', ' Patients who completed the Sunitinib monotherapy segment'], 'Eligibility': ['Inclusion Criteria:', ' Patients must have histologically-confirmed adenocarcinoma of the breast with operable or inoperable stage 1c (pri... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a5ed3500-1ea1-40b6-b1cb-3d5ae776f713 | |
Comparison | Eligibility | NCT00903162 | NCT01674062 | Patients with BCC are excluded from the primary trial and the secondary trial. | Contradiction | [
10,
12
] | [
6,
10
] | {'Clinical Trial ID': 'NCT00903162', 'Intervention': ['INTERVENTION 1: ', ' Letrozole-Leuprolide', ' Patients will receive 2.5mg oral letrozole daily and either 7.5mg monthly of Leuprolide IM or 22.5mg every three months of Leuprolide IM. Zoledronic acid 4mg IV every 6 months x 4 will also be offered optionally.', ' ... | {'Clinical Trial ID': 'NCT01674062', 'Intervention': ['INTERVENTION 1: ', ' Pertuzumab + Trastuzumab (Cohorts 1 and 2)', ' Females with HER2-positive metastatic breast cancer received dual-agent treatment with pertuzumab and trastuzumab. Recruitment for Cohorts 1 and 2 was conducted separately; however, the same regi... | 3c482d5e-bfad-4a46-9e98-ba9967f2d900 |
Single | Eligibility | NCT00654836 | Patients with metastatic HER-2-negative adenocarcinoma of the breast may be eligible for the primary trial. | Entailment | [
0,
1,
2,
3,
5
] | [] | {'Clinical Trial ID': 'NCT00654836', 'Intervention': ['INTERVENTION 1: ', ' Carboplatin, ABI-007 and Bevacizumab', " Participants received combination carboplatin, ABI-007 (i.e., a nanoparticle albumin-bound paclitaxel also called Abraxane), and bevacizumab (Avastin). Bevacizumab was administered as 15 mg/kg on days ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 48ccd744-abf1-4e98-bc86-8ecd625e6279 | |
Single | Eligibility | NCT01783444 | Women of any age can participate in the primary trial. | Entailment | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT01783444', 'Intervention': ['INTERVENTION 1: ', ' Everolimus 10 mg + Exemestane 25 mg', ' Everolimus (10 mg daily) with Exemestane (25 mg daily) (control arm).', 'INTERVENTION 2: ', ' Everolimus 10 mg', ' Everolimus (10 mg daily) (investigational arm).'], 'Eligibility': ['Key Inclusion Cri... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | dce5d9c8-7da6-4732-b969-c492c876cdca | |
Single | Results | NCT01106898 | 2% of the primary trial patients were diagnosed with Fatty Liver Disease after 3 years of Treatment with Chemotherapy or Maintenance Therapy. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT01106898', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Chemotherapy With or Without Maintenance Therapy)', ' SYSTEMIC CHEMOTHERAPY: Patients receive cyclophosphamide IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 1882de62-2df2-4b73-a3d2-81811f85f661 | |
Single | Eligibility | NCT00325234 | Patients wanting to participate in the primary trial, must discontinue any Antitumoral hormonal treatment, and must have a life expectancy of more than 3 months. | Entailment | [
0,
7,
8
] | [] | {'Clinical Trial ID': 'NCT00325234', 'Intervention': ['INTERVENTION 1: ', ' Pemetrexed/Carboplatin', ' Pemetrexed 600 mg/m^2 was administered intravenously over approximately 10 minutes on Day 1. Carboplatin was given over approximately 30 minutes on Day 1 beginning after the end of the Pemetrexed infusion, consisten... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 161c852e-a42c-47c2-ab6a-2b7bd6a4b934 | |
Single | Adverse Events | NCT01120184 | At least 1 patient in cohort 1 of the primary trial suffered from a Hemophilia, a rare coagulation disorder. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT01120184', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab + Taxane', " Participants received trastuzumab plus either docetaxel or paclitaxel. The regimen was chosen at the investigator's discretion. Option 1: trastuzumab 8 mg/kg via IV infusion on Day 1 of Cycle 1, then 6 mg/kg IV on Day... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | eb152d1b-a0d6-428c-8d1d-eb5d862a8147 | |
Comparison | Adverse Events | NCT00546156 | NCT00398567 | There are no cases of Vertigo in the primary trial or the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | {'Clinical Trial ID': 'NCT00546156', 'Intervention': ['INTERVENTION 1: ', ' HR+, HER2-', ' Patients with Hormone Receptor Positive, HER2 negative Breast Cancer. A single dose of Bevacizumab 10mg/kg, followed two weeks later by Adriamycin60 mg/m2 and Cyclophosphamide 600 mg/m2 with Bevacizumab 10mg/kg every 2 weeks x4... | {'Clinical Trial ID': 'NCT00398567', 'Intervention': ['INTERVENTION 1: ', ' Part 2 - Expanded MTD Cohort', ' All subjects receiving HKI-272 (neratinib) in combination with trastuzumab (Herceptin) HKI-272: neratinib 240 mg daily by mouth Herceptin: Herceptin 4 mg/kg IV as a loading dose followed by Herceptin 2 mg/kg w... | 0701ac32-45b3-4199-aa20-a71080ce9bf6 |
Comparison | Intervention | NCT03573804 | NCT02781051 | Participants of the primary trial must undergo at least one MRI during the intervention, in the secondary trial patients must use a fitbit. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6
] | {'Clinical Trial ID': 'NCT03573804', 'Intervention': ['INTERVENTION 1: ', ' Prone to Supine MRI Evaluated by Radiologist A', ' Radiologist A, number of participants successfully segmented', 'INTERVENTION 2: ', ' Prone to Supine MRI Evaluated by Radiologist B', ' Radiologist B, number of participants successfully se... | {'Clinical Trial ID': 'NCT02781051', 'Intervention': ['INTERVENTION 1: ', ' Physical Activity Intervention', ' Participants will participate in a multi-component physical activity intervention for 12 weeks with a 6 month follow up.', ' Print-based education: Subjects were given a copy of Exercise for Health: An Exer... | 866876f5-68de-44bd-b58a-e4b590aa4b39 |
Single | Results | NCT00370552 | There 55 more Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) in cohort 2 of the primary trial than in cohort 1. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00370552', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg', ' Ixabepilone,16 mg/m^2, administered as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, adm... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b4304362-1cb4-4606-9de4-03935ad509f1 | |
Comparison | Eligibility | NCT03097653 | NCT00662129 | Females aged between 18-25 with stable angina cannot be included in either the secondary trial or the primary trial. | Contradiction | [
0,
1,
2,
3,
4
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35,
36,
37,
38,
39,
40,
41,
42,
43,
44,
45,
46,
47,
48,
49,
50,
51,
52,
53,
54... | {'Clinical Trial ID': 'NCT03097653', 'Intervention': ['INTERVENTION 1: ', ' Decision-aid', " Decision-aid: Web platform with a multilevel information and an aid for the decision to be taken. The content is splitted in 16-20 screens; each screen contains the answer to a common question (i.e. What is mammography screen... | {'Clinical Trial ID': 'NCT00662129', 'Intervention': ['INTERVENTION 1: ', ' Paclitaxel + Gemcitabine + Bevacizumab', ' Patients receive 125 mg/m^2 paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and 1000 mg/m^2 gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and 15 mg/kg bevaci... | 9cddd86a-4340-4918-b000-7e6e593a3f7f |
Comparison | Adverse Events | NCT00528567 | NCT01196052 | The total number of patients affected by adverse events in cohort 2 the primary trial is more than 1000. | Contradiction | [
11,
12
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | {'Clinical Trial ID': 'NCT00528567', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab and Chemotherapy', ' Participants randomized to receive bevacizumab and chemotherapy', 'INTERVENTION 2: ', ' Chemotherapy', ' Participants randomized to receive chemotherapy alone'], 'Eligibility': ['Inclusion Criteria:', ' adu... | {'Clinical Trial ID': 'NCT01196052', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine', ' Trastuzumab emtansine 3.6 mg/kg was administered intravenously on Day 1 of each 3-week treatment cycle up to a maximum of 17 cycles.'], 'Eligibility': ['Inclusion Criteria:', ' Adult patients 18 years of age.', ' ... | c3f01101-2259-4677-add1-1b1f48a0202b |
Single | Results | NCT00143390 | In the primary trial There was less than 3 days difference between the maximum recorded TTP of the Exemestane group and the Anastrozole group. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00143390', 'Intervention': ['INTERVENTION 1: ', ' Exemestane', ' One tablet each of exemestane 25 mg and anastrozole placebo were orally administered once daily after a meal. The study treatment was continued until the disease progression or other discontinuation criteria were met.', 'INTERV... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 33b827a0-ada5-4204-abb8-d5239ea16f0b | |
Single | Results | NCT00259090 | the primary trial studies the impact of Fulvestrant, Anastrozole on Oestrogen Receptor H-score. | Entailment | [
1
] | [] | {'Clinical Trial ID': 'NCT00259090', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant', ' Fulvestrant 500 mg once monthly injection', 'INTERVENTION 2: ', ' Fulvestrant + Anastrozole', ' Fulvestrant 500 mg once monthly injection + Anastrozole 1 mg once daily tablet'], 'Eligibility': ['Inclusion Criteria:', ' Post... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 40f1d3ce-2ff8-4177-9b11-0bf10b7f6591 | |
Comparison | Results | NCT00802945 | NCT01231659 | Group 1 of the secondary trial has a higher ORR than both the NKTR-102 14 Day cohort of the primary trial and the NKTR-102 21 Days cohort. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | {'Clinical Trial ID': 'NCT00802945', 'Intervention': ['INTERVENTION 1: ', ' NKTR-102 14 Day', ' NKTR-102: NKTR-102 given on a q14 day schedule', 'INTERVENTION 2: ', ' NKTR-102 21 Days', ' NKTR-102: NKTR-102 given on a q21 day schedule'], 'Eligibility': ['Inclusion Criteria:', ' Inoperable metastatic or locally adv... | {'Clinical Trial ID': 'NCT01231659', 'Intervention': ['INTERVENTION 1: ', ' Everolimus + Letrozole', ' All patients received 2 tablets (5 mg each) of Everolimus (a total of 10 mg) + 1 tablet of Letrozole (2.5 mg) daily until disease progression or as described in the protocol.'], 'Eligibility': ['Inclusion Criteria:'... | 22bff413-a1bd-419b-b19b-2157dedc9948 |
Single | Intervention | NCT00880022 | Only patients in cohort 2 of the primary trial undergo Trunk compression. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00880022', 'Intervention': ['INTERVENTION 1: ', ' Arm Compression Only', '[Not Specified]', 'INTERVENTION 2: ', ' Arm, Trunck and Chest Compression', '[Not Specified]'], 'Eligibility': ['Inclusion Criteria:', ' Individuals at least six months post- surgery and/or radiation treatment for bre... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b64d6e41-7ec7-4e62-beda-c28559a6cee7 | |
Single | Adverse Events | NCT01875367 | More than 3 patients in the primary trial had a common cold. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [] | {'Clinical Trial ID': 'NCT01875367', 'Intervention': ['INTERVENTION 1: ', ' Arm A: T-IV + T-SC Vial + T-SC Device', ' Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with vial (Injectable Solution) x 2 cycles, followed by 600mg of T-SC with si... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2ea80a50-0db3-4ff2-8ca0-71eb048649f7 | |
Comparison | Eligibility | NCT00880464 | NCT00458237 | Patients with AIDS are eligible for both the secondary trial and the primary trial. | Contradiction | [
14,
18
] | [
12,
26
] | {'Clinical Trial ID': 'NCT00880464', 'Intervention': ['INTERVENTION 1: ', ' Vaccine', 'Biological/Vaccine: Autologous, Lethally Irradiated Breast Cancer Cells Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out', ' Autologous, Lethally Irradiated Breast Cancer... | {'Clinical Trial ID': 'NCT00458237', 'Intervention': ['INTERVENTION 1: ', ' Phase I: Everolimus (Dose Level 1) and Trastuzumab', ' Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus 5 mg by mouth daily on days 1-21. Participants are... | 20545360-b2a1-4be9-997a-97040866b239 |
Comparison | Results | NCT02425891 | NCT00593827 | the secondary trial and the primary trial both measure PFS of their patient cohorts and use the same time frame. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT02425891', 'Intervention': ['INTERVENTION 1: ', ' Placebo Plus Nab-Paclitaxel', ' Participants assigned to placebo plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.', 'INTERVENTION 2: ', ' Atezolizumab Plus Nab-Paclitaxel', ' Participants assigned... | {'Clinical Trial ID': 'NCT00593827', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone 16 mg/m^2', ' ixabepilone 16 mg/m^2 weekly for 3 weeks followed by 1 week rest', 'INTERVENTION 2: ', ' Ixabepilone 40 mg/m^2', ' ixabepilone 40 mg/m^2 every 3 weeks'], 'Eligibility': ['Inclusion Criteria:', ' Has MBC that is me... | 3b1bdc19-62cd-4ff1-9e30-424e124342f3 |
Comparison | Adverse Events | NCT01466972 | NCT01446159 | the primary trial recorded one patient with congestive heart failure, the secondary trial did not record any. | Entailment | [
0,
2
] | [
0,
5,
13,
18
] | {'Clinical Trial ID': 'NCT01466972', 'Intervention': ['INTERVENTION 1: ', ' Pazopanib in Combination With a NSAI', ' Non-randomized, open label', ' Pazopanib: Oral, 800mg tablet daily per cycle'], 'Eligibility': ['Inclusion Criteria:', ' Subjects must provide written informed consent prior to performance of study s... | {'Clinical Trial ID': 'NCT01446159', 'Intervention': ['INTERVENTION 1: ', ' MEDI-573 10 mg/kg + Aromatase Inhibitor (AI)', " Participants enrolled in Phase 1b of the study and received intravenous infusion of MEDI-573 10 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, ... | a44cd0d1-92b3-4add-badf-b8dd5a324138 |
Comparison | Intervention | NCT01738438 | NCT00331552 | Cyclophosphamide, Cabozantinib and Trastuzumab were used in the secondary trial intervention, but not in the primary trial. | Contradiction | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01738438', 'Intervention': ['INTERVENTION 1: ', ' Cabozantinib', ' Cabozantinib was given at a dose of 60 mg orally once per day for 21 day cycles. Treatment continued in the absence of disease progression or unacceptable toxicity.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically ... | {'Clinical Trial ID': 'NCT00331552', 'Intervention': ['INTERVENTION 1: ', ' Phase I: Cyclophosphamide, Doxil, Trastuzumab', ' Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease p... | 291bb67e-f02f-49d4-b967-29cc9f5098c4 |
Comparison | Eligibility | NCT00274768 | NCT00654836 | Patients with stage 4 cancer are eligible for the secondary trial and the primary trial. | Entailment | [
2
] | [
2
] | {'Clinical Trial ID': 'NCT00274768', 'Intervention': ['INTERVENTION 1: ', ' Capecitabine', ' The starting dose of capecitabine was 3,000 mg (total daily dose) given in two divided daily doses for 14 days followed by 7 days of rest (1 cycle = 21 days). Missed doses were not substituted. Treatment was continued until u... | {'Clinical Trial ID': 'NCT00654836', 'Intervention': ['INTERVENTION 1: ', ' Carboplatin, ABI-007 and Bevacizumab', " Participants received combination carboplatin, ABI-007 (i.e., a nanoparticle albumin-bound paclitaxel also called Abraxane), and bevacizumab (Avastin). Bevacizumab was administered as 15 mg/kg on days ... | 55704a1f-eab2-44ea-a6de-8df508a28066 |
Comparison | Eligibility | NCT01593020 | NCT00834678 | Patients with aspartate aminotransferase more than 3 times the upper limit of normal are excluded from both the secondary trial and the primary trial. | Entailment | [
13,
18
] | [
23
] | {'Clinical Trial ID': 'NCT01593020', 'Intervention': ['INTERVENTION 1: ', ' Paclitaxel Weekly for 12 Doses Followed by FAC/FEC', ' Patients will receive Paclitaxel 80 mg/m2 IVPB over 1 hour weekly for 12 doses followed by FAC/FEC.', 'INTERVENTION 2: ', ' Eribulin on Days 1 and 8 Every 3 Weeks for 4 Cycles (21 Day Cy... | {'Clinical Trial ID': 'NCT00834678', 'Intervention': ['INTERVENTION 1: ', ' Bendamustine and Erlotinib', ' Participants in dose level I were administered 100 mg/m^2 IV of Bendamustine on days 1 and 2 and 100 mg PO of Erlotinib on days 5 - 21 of each 28 day cycle.', ' Participants in dose level II were administered 1... | 6e1955b8-e6fa-42b2-a498-7ada9e733304 |
Single | Eligibility | NCT00821886 | Patients prescribed with bisoprolol or labetalol to treat CHF are eligible for the primary trial. | Contradiction | [
20,
33
] | [] | {'Clinical Trial ID': 'NCT00821886', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone/Trastuzumab/Carboplatin', ' Neoadjuvant treatment with Ixabepilone, Trastuzumab and Carboplatin, followed by surgery, peri-operative treatment and post-operative (adjuvant) treatment if patient deemed to be a surgical candidate', ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 52337e14-7f51-40c1-b965-fb6aba8ae4e7 | |
Single | Eligibility | NCT00004092 | Patients with Cancer that has spread from a breast tumor to their CNS are able to take part in the primary trial. | Contradiction | [
4
] | [] | {'Clinical Trial ID': 'NCT00004092', 'Intervention': ['INTERVENTION 1: ', ' Arm I (ACT)', ' Patients receive 41.25 mg/m2 of doxorubicin IV over 24 hours on days -9 to -6, 100 mg/kg of cyclophosphamide IV over 2 hours on day -5, and 725 mg/m2 of paclitaxel IV over 24 hours on day -4. PBSC are reinfused on days -2 and ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8a6397e9-84cd-4a2e-ac6a-b56ee355d862 | |
Comparison | Intervention | NCT01401959 | NCT00852930 | the primary trial designates specific interventions to its patients depending on their hormone status, Cohort A is TNBC patients and cohort B is ER/PR +HER2- BC Patients, in contrast the secondary trial assigns interventions randomly. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT01401959', 'Intervention': ['INTERVENTION 1: ', ' Cohort A: Triple-negative Breast Cancer Patients', ' Patients with triple-negative breast cancer who do not have a pathological complete response following neoadjuvant therapy and surgery will receive eribulin 1.4 mg/m^2 on Days 1 and 8 every... | {'Clinical Trial ID': 'NCT00852930', 'Intervention': ['INTERVENTION 1: ', ' Laser Therapy Alone', ' therapist administered laser treatment', ' laser: therapist administered laser', 'INTERVENTION 2: ', ' Mld Alone', ' therapist administered manual lymphatic drainage', ' manual lymphatic drainage: therapist adminis... | 8b5f946c-71d9-42cd-aa9a-1d3a4845c460 |
Comparison | Intervention | NCT01852032 | NCT01118624 | the secondary trial administers placebo tablets at twice the rate of the primary trial, but less than half the dose. | Contradiction | [
0,
1,
2
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT01852032', 'Intervention': ['INTERVENTION 1: ', ' Breast Cancer Patients', ' Tomosynthesis Breast Scanning is done and breast CT Scanning is done.'], 'Eligibility': ['Inclusion Criteria:', ' 35 years of age or older', ' While male patients will not be explicitly excluded, it is expected th... | {'Clinical Trial ID': 'NCT01118624', 'Intervention': ['INTERVENTION 1: ', ' Pralatrexate', ' Study drug 190 mg/m^2 for 2 to 4 weeks.'], 'Eligibility': ['Inclusion Criteria:', ' HER-2 negative advanced or metastatic breast cancer', ' Disease has become worse after at least 1 prior chemotherapy regimen for advanced o... | 8f0aff7f-0d9e-498b-bcb6-05e6d309724c |
Comparison | Results | NCT00313170 | NCT00305448 | Patients in the primary trial treated with Fulvestrant 250 mg had a 33% higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16
] | {'Clinical Trial ID': 'NCT00313170', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant 250 mg', 'Fulvestrant 250 mg', 'INTERVENTION 2: ', ' Fulvestrant 250 mg + Loading Dose', ' Fulvestrant 250 mg + Loading Dose'], 'Eligibility': ['Inclusion Criteria:', ' Breast Cancer has continued to grow after having received t... | {'Clinical Trial ID': 'NCT00305448', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant 250 mg', 'Fulvestrant 250 mg', 'INTERVENTION 2: ', ' Fulvestrant 250 mg + Loading Dose', ' Fulvestrant 250 mg + Loading Dose'], 'Eligibility': ['Inclusion Criteria:', ' Breast Cancer has continued to grow after having received t... | b7936bbc-f0c0-444c-a199-2db323c30396 |
Comparison | Intervention | NCT01373671 | NCT00686127 | Lidoderm products are used in intervention arm 1 of the secondary trial, and a Siemens product is used in arm 1 of the primary trial | Entailment | [
0,
1,
2
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT01373671', 'Intervention': ['INTERVENTION 1: ', ' FFDM and DBT', ' FFDM exam and DBT scan on Siemens MAMMOMAT Inspiration', 'INTERVENTION 2: ', ' FFDM Only', 'FFDM exam only'], 'Eligibility': ['Inclusion Criteria:', ' All subjects enrolled into the collection study must:', ' Provide signe... | {'Clinical Trial ID': 'NCT00686127', 'Intervention': ['INTERVENTION 1: ', ' Lidocaine Patch', ' Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.): 1 patch was applied topically to the affected site(s) for 12 hours each day.', 'INTERVENTION 2: ', ' Placebo Patch', ' Placebo patch: 1 patch was applied topical... | 6d6625ec-26b7-4157-a38c-87c770201323 |
Single | Eligibility | NCT01305941 | Patients must present IHC 3+ or FISH amplified results to participate in the primary trial, meaning their cancer is Histologically-confirmed as being triple-positive. | Contradiction | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT01305941', 'Intervention': ['INTERVENTION 1: ', ' Everolimus +Vinorelbine + Trastuzumab', ' daily everolimus plus weekly (Days 1, 8, and 15) vinorelbine and trastuzumab', ' Everolimus: everolimus 5 mg PO daily as two 2.5-mg tablets', ' Vinorelbine: vinorelbine 25 mg/m2 will be administered... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e8b8c2b7-612d-4bab-b8a6-3dbc756cc210 | |
Single | Intervention | NCT00606931 | the primary trial tests MRI scanning as a technique for guiding biopsies. | Contradiction | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00606931', 'Intervention': ['INTERVENTION 1: ', ' PET Guided Biopsy', ' No comparison group. All enrolled participants were expected to undergo PET guided biopsy.'], 'Eligibility': ['Inclusion Criteria:', ' Individuals aged 25 years or older', ' Individuals who have at least one breast ima... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7e0259a3-073b-45f5-8e08-2cfaceecef0b |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.